P ediatric use of medical cannabis entered widespread public consciousness in 2013, when the CNN television network aired Weed, a documentary highlighting its therapeutic benefits in children with severe epilepsy. 1 Since then, pediatric medical cannabis has continued to gain societal and scientific attention. [2][3][4][5] Cannabis contains 2 main cannabinoids with proposed medicinal effects: cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). 6 Cannabidiol reduces seizure frequency and duration in children with treatmentresistant epilepsy, 7 specifically Dravet syndrome; 8-10 THC is known to have antiemetic, appetite-stimulant and analgesic effects useful in cancer treatment. [11][12][13][14][15] We use the term medical cannabis for any combination of CBD and THC.In 2018, Canada became the second nation to legalize cannabis for both recreational and medical use. Products under pharmaceutical regulations (Controlled Drugs and Substances Act [S.C 1996, c. 19]) are available via prescription as semisynthetic drugs 16 or highly purified plant-derived drugs. 17 Nonpharmaceutical, standardized cannabis extracts are available with medical authorization from more than 150 licensed producers, (Cannabis Act [S.C. 2018, c. 16]). Additionally, adults may obtain cannabis intended for recreational use, without medical authorization, from retail stores, called dispensaries, or black market sources. 18,19 Provenance of cannabis from dispensaries is often unknown. Cannabis can also be grown at home.There is a lack of robust evidence to guide cannabis practices across pediatric medical disciplines. 2,20,21 The Canadian Paediatric Society does not support its use, except on a carefully considered, case-by-case basis, citing limited evidence and potential harms. 2 Thus, in Canada, use of medical cannabis is most known in children with severe conditions. Few

ObjectivesThe objective of this study was to explore parent perspectives of and interest in an interactive knowledge translation platform called Child-Sized KT that proposes to catalyse the collaboration of patients, families, practitioners and researchers in patient-oriented research at British Columbia Children’s Hospital (BCCH).MethodsAn explanatory sequential mixed methods design was used over 1 year. Over 500 parents across BC completed an online survey, including a subsample of 102 parents who had accessed care at BCCH within the past 2 years. The survey explored parent perspectives about the value of their engagement at all stages of the research process and their interest in and concerns with using an online platform. Following the online survey, two focus groups were held with parents in the Vancouver area to explore themes emerging from the survey.ResultsParents expressed keen interest in engaging in research at BCCH. Parents perceived benefit from their input at all stages of the research process; however, they were most interested in helping to identify the problem, develop the research question and share the results. Although parents preferred online participation, they had concerns about protecting the privacy of their child’s information.ConclusionsParents see value in their involvement in all stages of child health research at BCCH. Their input suggests that Child-Sized KT, a hypothetical online platform, would facilitate meaningful stakeholder engagement in child health research, but should offer a customised experience and ensure the highest standard of data privacy and protection.